Cassava Sciences | PTIE - Selling And Administration Expenses


Cassava Sciences reported $7.9M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.13B 125M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
Cara Therapeutics USD 4.64M 2.19M Mar/2025
Cassava Sciences USD 7.9M 1.08M Sep/2025
Eisai JPY 111.72B 7.86B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Geron USD 39M 437K Sep/2025
J&J USD 6.75B 831M Dec/2025
Merck USD 2.85B 215M Dec/2025
Novartis USD 3.31B 134M Sep/2025
Novavax USD 66.95M 34.05M Sep/2024
Pfizer USD 4.08B 894M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025